In 2005, multiple groups identified a high frequency of the V617F (G→T) mutation in the tyrosine kinase gene JAK2 as the most common molecular abnormality in chronic myeloproliferative disorders. Before 2005, there had been no recurring cytogenetic abnormality described at a high incidence in these disorders. The initial descriptions could well be classified as discovery papers because each group used sequencing of the JAK2 gene in established cases of each myeloproliferative disorder. [1] [2] [3] [4] [5] These studies demonstrated that the highest frequency of this somatic JAK2 mutation occurred in polycythemia vera (65%-97%), with a lesser frequency (23%-57%) in essential thrombocythemia and idiopathic myelofibrosis ❚Table 1❚. [1] [2] [3] [4] [5] No other mutation site in JAK2 was identified. This unique valine to phenylalanine substitution at position 617 results in proliferative advantages for hematopoietic precursors 4 that are hypersensitive to cytokines. 3 It is not surprising that JAK2 mutations have been identified at a low incidence in acute myeloid leukemia and in rare cases of myelodysplastic syndrome. It is well known that chronic myeloproliferative disorders may transform into acute leukemia; therefore, some cases may not have manifested in the chronic phase. Other patients have mixed findings in which the differential diagnosis is difficult, such as in chronic myelomonocytic leukemia, which also has been shown to have a low incidence of JAK2 mutations. 6 The goal of this editorial is to discuss the development of diagnostic methods for the JAK2 V617F mutation. It is not intended to be a review of the pathogenesis of JAK2 mutations or the clinical correlations identified to date. Why are there variations in the incidence rate in the patient series? This variation likely is due to the different clinical criteria used for diagnosis, the extent of involvement by the clonal proliferation at the time of specimen collection, and the difference in performance by the assays used to detect the mutation.
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Development of Detection Methods
As usually follows a discovery of new genetic information, molecular geneticists and molecular pathologists strive to develop a diagnostic assay that is of greatest usefulness in assessing a clinical specimen for patient care. Beginning in the latter part of 2005 and now in 2006, we are observing the description of such assays. The DNA sequence spanning the JAK2 mutation site has the appropriate melting characteristics to potentially allow the use of a variety of methods that can discriminate the G→T mutation from the wild-type sequence ❚Table 2❚. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In the April issue of the Journal, Murugesan and colleagues 7 described the use of melting curve analysis for the detection of the JAK2 V617F mutation. Their study shows that the difference of a single nucleotide results in a wide 8°C separation in the melting temperature of the mutant and wild-type DNA sequences. This is similar to the 6°C to 10°C spread that has been described by 2 other groups using FRET probes and melting curve analysis. 9, 10 This great difference in the melting temperature of the DNA should allow for alternative approaches, such as denaturing gradient gel electrophoresis, singlestrand conformation polymorphism, temperature gradient gel electrophoresis, and denaturing high-performance liquid chromatography, 5 to achieve an easy separation of the mutant from wild-type sequence. However, some of these latter techniques encompass a time-consuming and labor-intensive gel electrophoresis or an additional post-polymerase chain reaction (PCR) analysis step. There is an inherent advantage then in an approach such as melting curve analysis, in which the diagnostic information is immediately available at the end of the amplification period.
Although melting curve analysis may perform well in the initial diagnostic specimen, there is difficulty in discriminating a low-level "shoulder" reproducibly in populations of fewer than 1% to 10% of the aberrant cells. 7, 9, 10 This predicts that other methods will perform better for follow-up testing. These tests may include quantitative real-time PCR analysis with a Taqman, FRET, or minor groove binding probe, estimated with a standard curve of dilutions of the HEL cell line in normal DNA. 10 Alternatively, allele-specific oligonucleotide PCR using quantitative analysis of the area under the curve in electropherograms of capillary electrophoresis may be successful. 9 Allele-specific oligonucleotide PCR and quantitative real-time PCR analysis are likely to be the most sensitive techniques (Table 2 ). Traditional sequencing is not very sensitive when the mutant sequence is less than 25% of the DNA present; however, pyrosequencing has been reported to reach a detection level of 5%. 5, 6 Restriction fragment length polymorphism also is relatively insensitive at low levels of disease.
Future of JAK2 Mutation Detection
Targeted therapy may have a high likelihood of success in treating these disorders, following the model of imatinib mesylate in chronic myelogenous leukemia. Investigators already have shown that reduction of cell growth and colony formation can be obtained using small interfering RNA and small molecule inhibitor therapy in in vitro experiments. 2, 3 How will successful therapy affect diagnostic laboratories? One can anticipate that follow-up analysis will become more frequent than initial diagnostic assays. This will generate the need for a quantitative assay for low-level disease. To date, the published information suggests that separation of granulocytes may be very important for the identification of low-level disease. This step, which could be accomplished by separation gradient, flow sorting, or magnetic bead separation, is necessary because the somatic mutation is not present in lymphocytes. 1, 4 Future correlative studies will determine whether there is a significant clinical need to discriminate whether the tumor cells are homozygous or heterozygous for the mutation. The data are limited, and the validation of the homozygous mutation status of the patient's tumors by various techniques is not well established. More studies will need to be done in this area. More work also needs to be done on the comparative performance between diagnostic assays that have been described in the literature.
Development of Clinical Recommendations for Testing
The identification of JAK2 mutations has been of intense interest to hematologists and molecular pathologists during the last 12 months. An educational session and a special plenary session on myeloproliferative disorders to discuss the implications of these recent discoveries were offered at the December 2005 American Society of Hematology meeting. 11 Presentations and posters on method development were shared at the November 2005 Association for Molecular Pathology meeting and the February 2006 US and Canadian Academy of Pathology meeting. These meetings have led to the developing recommendation that screening for the JAK2 mutation be performed when a diagnosis of a myeloproliferative disorder is considered. Several diagnostic algorithms for the evaluation of erythrocytosis were reported recently. [10] [11] [12] 
Conclusion
The identification of the JAK2 mutation is a major discovery to help hematologists and pathologists understand the molecular pathogenesis of chronic myeloproliferative disorders. It will be exciting to see what therapies are developed to help patients with these disorders. 
